PASADENA, Calif., April 16 /PRNewswire-FirstCall/ -- Arrowhead Research Corporation (Nasdaq: ARWR - News) announced today that two of its majority-owned subsidiaries, Insert Therapeutics Inc. and Calando Pharmaceuticals Inc., are presenting data at the 2007 American Association for Cancer Research (AACR) Annual Meeting. The presentations summarize the latest research findings on two anticancer therapies currently under development. Both therapies employ a novel delivery system called Cyclosert(TM), developed at the California Institute of Technology and exclusively licensed to Insert Therapeutics and, through Insert, to Calando.
